text: 6/ ...goes well beyond the deregulation favored by most pharmaceutical executives."
  
  🔹️Pharma also likes FDA nom. Makary, who's "not seen as a threat to unwind the status quo," & fed. funding slasher Ramaswamy, "who made his fortune as a biotechnology executive and...has been critical of what he...